Ales Sorf
Hradec Kralove, KR 50003, Czech Republic
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Carltonine B derivatives: Synthesis and structure-activity relationship insights for selective butyrylcholinesterase inhibition.
Journal: Bioorganic chemistry
Published: February 11, 2026
Novel antitubercular agents based on 2,4-disubstituted 5-(aryl-2-ylmethyl)-5H-pyrrolo[3,2-d]pyrimidines.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: July 23, 2025
Novel tacrine-based multi-target directed Ligands: Enhancing cholinesterase inhibition, NMDA receptor antagonism, and CNS bioavailability for Alzheimer's disease treatment.
Journal: European journal of medicinal chemistry
Published: March 05, 2025
Multifunctional, Fluorene-Based Modulator of Cholinergic and GABAergic Neurotransmission as a Novel Drug Candidate for Palliative Treatment of Alzheimer's Disease.
Journal: Angewandte Chemie (International ed. in English)
Published: October 23, 2024
Targeting FMS-like tyrosine kinase 3 (FLT3) in acute myeloid leukemia: Novel molecular approaches and therapeutic challenges.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: October 09, 2024
Carltonine-derived compounds for targeted butyrylcholinesterase inhibition.
Journal: RSC medicinal chemistry
Published: January 23, 2024
Differentiated SH-SY5Y neuroblastoma cells as a model for evaluation of nerve agent-associated neurotoxicity.
Journal: Archives of toxicology
Published: March 13, 2023
ABCB1 as a potential beneficial target of midostaurin in acute myeloid leukemia.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: January 28, 2022
Dabrafenib inhibits ABCG2 and cytochrome P450 isoenzymes; potential implications for combination anticancer therapy.
Journal: Toxicology and applied pharmacology
Published: July 13, 2021
Targeting Pharmacokinetic Drug Resistance in Acute Myeloid Leukemia Cells with CDK4/6 Inhibitors.
Journal: Cancers
Published: April 21, 2020
S-(4-Nitrobenzyl)-6-thioinosine (NBMPR) is Not a Selective Inhibitor of Equilibrative Nucleoside Transporters but Also Blocks Efflux Activity of Breast Cancer Resistance Protein.
Journal: Pharmaceutical research
Published: November 25, 2019
Brivanib Exhibits Potential for Pharmacokinetic Drug-Drug Interactions and the Modulation of Multidrug Resistance through the Inhibition of Human ABCG2 Drug Efflux Transporter and CYP450 Biotransformation Enzymes.
Journal: Molecular pharmaceutics
Published: October 22, 2019
Last Updated: 09/26/2026